Hereby, GLP-1RAs can diminish STAT1 activity [91]
Patent No.10,278,923 was filed on July 17, 2017, and was granted on May 7, 2019
Chapters: 00:00 Intro & Podcast Catch-Up 11:13 Peptide Testing & Quality Concerns 20:16 IGF-1, HGH & Stack Overlap 29:20 Womens Hormones & Hysterectomy 32:15 Menopause, Weight Gain & Peptides 44:16 Peptide Storage & Shelf Life 49:44 NAD+ Crystallization Explained 51:37 Growth Hormones for Women (Age 44) 59:44 Low Testosterone & Mental Health (Age 28) 1:05:48 Building Muscle Without Steroids (Athlete Q&A) We cover: Why Peptide Companies Don't Test for Endotoxins & Heavy Metals: The real cost breakdown, why cheap peptides come with trade-offs, and how quality standards are rising Kisspeptin on TRT Why It Won't Work: How TRT shuts down the signal kisspeptin needs and why HCG is the smarter choice for testicular health on cycle IGF-1 LR3 Stacking Rules: Why combining HGH, secretagogues, and IGF-1 all at once is too much on the same pathway and how to rotate smarter Peptide Shelf Life & Storage Explained: Bacteriostatic vs
For researchers transitioning from other compounds, the retatrutide dosage schedule after tirzepatide and switching protocols provide guidance on cross-compound transitions based on available research data
Retatrutide is currently an investigational drug and is not FDA-approved
